| Dr Firdous Laique, MD | |
|
7777 Hennessy Blvd, Suite 103, Baton Rouge, LA 70808-4300 | |
| (225) 767-6700 | |
| (225) 767-6721 |
| Full Name | Dr Firdous Laique |
|---|---|
| Gender | Female |
| Speciality | Pediatrics - Pediatric Critical Care Medicine |
| Location | 7777 Hennessy Blvd, Baton Rouge, Louisiana |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1457350860 | NPI | - | NPPES |
| 1466174 | Medicaid | LA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2080P0203X | Pediatrics - Pediatric Critical Care Medicine | 15490R (Louisiana) | Primary |
| Entity Name | Pediatric Intensivists Of La, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1538171327 PECOS PAC ID: 3072413152 Enrollment ID: O20040113000604 |
News Archive
Acceleron Pharma, a biopharmaceutical company developing protein therapeutics for cancer and orphan disease, today announced that the Gynecologic Oncology Group (GOG) initiated a phase 2 study of dalantercept in patients with persistent or recurrent ovarian, fallopian tube, or primary peritoneal cancer.
Tioga Pharmaceuticals, Inc. and Ono Pharmaceutical Co, Ltd. Osaka, Japan today announced an exclusive license agreement under which Ono has licensed rights to develop and commercialize asimadoline in Japan, South Korea and Taiwan. Tioga retains all other rights to asimadoline.
Study shows calcium intake mitigates genetic risk for increased body fat in African-American children, a population with historically low calcium intake and high risk for diabetes.
Pfizer Inc. and Protalix BioTherapeutics, Inc. announced today that the United States (U.S.) Food and Drug Administration (FDA) approved ELELYSO (taliglucerase alfa) for injection, an enzyme replacement therapy (ERT) for the long-term treatment of adults with a confirmed diagnosis of type 1 Gaucher disease.
› Verified 7 days ago
| Entity Name | Baton Rouge General Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1215199724 PECOS PAC ID: 4082600077 Enrollment ID: O20081121000299 |
News Archive
Acceleron Pharma, a biopharmaceutical company developing protein therapeutics for cancer and orphan disease, today announced that the Gynecologic Oncology Group (GOG) initiated a phase 2 study of dalantercept in patients with persistent or recurrent ovarian, fallopian tube, or primary peritoneal cancer.
Tioga Pharmaceuticals, Inc. and Ono Pharmaceutical Co, Ltd. Osaka, Japan today announced an exclusive license agreement under which Ono has licensed rights to develop and commercialize asimadoline in Japan, South Korea and Taiwan. Tioga retains all other rights to asimadoline.
Study shows calcium intake mitigates genetic risk for increased body fat in African-American children, a population with historically low calcium intake and high risk for diabetes.
Pfizer Inc. and Protalix BioTherapeutics, Inc. announced today that the United States (U.S.) Food and Drug Administration (FDA) approved ELELYSO (taliglucerase alfa) for injection, an enzyme replacement therapy (ERT) for the long-term treatment of adults with a confirmed diagnosis of type 1 Gaucher disease.
› Verified 7 days ago
| Entity Name | Our Lady Of The Lake Physician Group Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1033494943 PECOS PAC ID: 4587849781 Enrollment ID: O20120529000377 |
News Archive
Acceleron Pharma, a biopharmaceutical company developing protein therapeutics for cancer and orphan disease, today announced that the Gynecologic Oncology Group (GOG) initiated a phase 2 study of dalantercept in patients with persistent or recurrent ovarian, fallopian tube, or primary peritoneal cancer.
Tioga Pharmaceuticals, Inc. and Ono Pharmaceutical Co, Ltd. Osaka, Japan today announced an exclusive license agreement under which Ono has licensed rights to develop and commercialize asimadoline in Japan, South Korea and Taiwan. Tioga retains all other rights to asimadoline.
Study shows calcium intake mitigates genetic risk for increased body fat in African-American children, a population with historically low calcium intake and high risk for diabetes.
Pfizer Inc. and Protalix BioTherapeutics, Inc. announced today that the United States (U.S.) Food and Drug Administration (FDA) approved ELELYSO (taliglucerase alfa) for injection, an enzyme replacement therapy (ERT) for the long-term treatment of adults with a confirmed diagnosis of type 1 Gaucher disease.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Firdous Laique, MD 7777 Hennessy Blvd, Suite 103, Baton Rouge, LA 70808-4300 Ph: (225) 767-6700 | Dr Firdous Laique, MD 7777 Hennessy Blvd, Suite 103, Baton Rouge, LA 70808-4300 Ph: (225) 767-6700 |
News Archive
Acceleron Pharma, a biopharmaceutical company developing protein therapeutics for cancer and orphan disease, today announced that the Gynecologic Oncology Group (GOG) initiated a phase 2 study of dalantercept in patients with persistent or recurrent ovarian, fallopian tube, or primary peritoneal cancer.
Tioga Pharmaceuticals, Inc. and Ono Pharmaceutical Co, Ltd. Osaka, Japan today announced an exclusive license agreement under which Ono has licensed rights to develop and commercialize asimadoline in Japan, South Korea and Taiwan. Tioga retains all other rights to asimadoline.
Study shows calcium intake mitigates genetic risk for increased body fat in African-American children, a population with historically low calcium intake and high risk for diabetes.
Pfizer Inc. and Protalix BioTherapeutics, Inc. announced today that the United States (U.S.) Food and Drug Administration (FDA) approved ELELYSO (taliglucerase alfa) for injection, an enzyme replacement therapy (ERT) for the long-term treatment of adults with a confirmed diagnosis of type 1 Gaucher disease.
› Verified 7 days ago
Manish Gope Raisingani, Pediatrics Medicare: Medicare Enrolled Practice Location: 8200 Constantin Blvd Fl 4, Baton Rouge, LA 70809 Phone: 225-765-5500 Fax: 225-765-1733 | |
Dr. Daniel Gregg Sloven, MD Pediatrics Medicare: Medicare Enrolled Practice Location: 8200 Constantin Blvd Fl 4, Baton Rouge, LA 70809 Phone: 225-765-5500 Fax: 225-765-2054 | |
Traci T. Lacy, MD Pediatrics Medicare: Accepting Medicare Assignments Practice Location: 7373 Perkins Rd, Baton Rouge, LA 70808 Phone: 225-769-4044 | |
Dr. Michelle L Flechas, M.D. Pediatrics Medicare: Medicare Enrolled Practice Location: 12525 Perkins Rd, Suite C, Baton Rouge, LA 70810 Phone: 225-769-2003 Fax: 225-767-3055 | |
Dr. Richard Francis Lasseigne Jr., MD Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 8300 Constantin Blvd, Baton Rouge, LA 70809 Phone: 225-374-1410 Fax: 225-374-1616 | |
Dr. Horace Jay Collinsworth, M.D. Pediatrics Medicare: Medicare Enrolled Practice Location: 8415 Goodwood Blvd, Suite 100, Baton Rouge, LA 70806 Phone: 225-765-5633 Fax: 225-765-5634 | |
Myriam Aracelis Ortiz-de Jesus', MD Pediatrics Medicare: Medicare Enrolled Practice Location: 11424 Sullivan Rd, Suite B1, Baton Rouge, LA 70818 Phone: 225-761-5200 |